skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

Nichi-Iko Pharmaceutical to Acquire Sagent Pharmaceuticals

Paul, Weiss client Nichi-Iko Pharmaceutical Co., Ltd., the largest generic drug manufacturer in Japan by sales, announced that it has agreed to acquire Sagent Pharmaceuticals, Inc. in an all-cash tender offer followed by a second-step cash merger, for a total consideration of approximately $736 million. This transaction is the next step in Nichi-Iko's announced strategy to become one of the world's top 10 generic drug makers. The signing concluded a lengthy and challenging auction process. The transaction is expected to close in the third quarter of 2016.

The Paul, Weiss team included corporate partners Toby Myerson and Tong Yu and counsel Scott Grader, Chikara Momota and Patricia Vaz de Almeida; finance partner Dale Sarro and counsel Stephen Koo; employee benefits partner Lawrence Witdorchic and counsel Jason Ertel; tax partner Richard Bronstein; intellectual property partner Claudine Meredith-Goujon; litigation partners Stephen Lamb, Walter Ricciardi and Catherine Nyarady and counsel Peter Sandel; international trade counsel Richard Elliott; environmental counsel William J. O'Brien; real estate partner Peter Fisch; and antitrust counsel Marta Kelly.

July 10, 2016

© 2019 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy